Comparison of Three Immunosuppressive Regimens in Cadaver Renal Transplantation: Long-Term Cyclosporine, Short-Term Cyclosporine Followed by Azathioprine and Prednisolone, and Azathioprine and Prednisolone without Cyclosporine

New England Journal of Medicine

Volumn 318, Issue 23, 1988, Pages 1499-1507

  Hall, Bruce M ^a   Tiller, David J ^a   Hardie, Ian ^b   Mahony, John ^c   Mathew, Timothy ^d   Thatcher, Geoffry ^e   Miach, Peter ^f   Thomson, Napier ^g   Sheil, A g Ross ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Princess Alexandra Hospital Woolloongabba   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

^e SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

CADAVER KIDNEY; DRUG THERAPY; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0023890235     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198806093182304     Document Type: Article

References (39)

1. Calne RY, Rolles K, White DJG, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033–6.
2. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2: 986–9.
3. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809–15.
4. Najarian J, Strand M, Fryd DS, et al. Comparison of cyclosporine versus azathioprine-antilymphocyte globulin in renal transplantation. Transplant Proc 1983; 15: 2463–8.
5. Hall BM, Tiller DJ, Horvath JS, et al. Treatment of renal transplantation rejection: cyclosporin A versus conventional treatment with azathioprine, prednisone and antithymocyte immunoglobulin in primary cadaveric renal transplantation. Med J Aust 1985; 142: 179–85.
6. Halloran P, Ludwin D, Aprile M, Canadian Multicentre Transplant Study Group. Comparison of antilymphocyte globulin, imuran, cyclosporine, and antilymphocyte globulin-cyclosporine therapy for cadaver renal transplantation. Transplant Proc 1985; 17: 1201–3.
7. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporineassociated chronic nephropathy. N Engl J Med 1984; 311: 699–705.
8. Palestine AG, Austin HA III, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293–8.
9. Von Graffenried B, Harrison WB. Renal function in patients with autoimmune diseases treated with cyclosporine. Transplant Proc 1985; 17: Suppl 1: 215–31.
10. Berg KJ, Førre O, Bjerkhoel F, et al. Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 1986; 29: 1180–7.
11. Morris PJ, French ME, Dunnhill MS, et al. A controlled trial of cyclosporin in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983; 36: 273–7.
12. Land VW, Castro LA, Hillebrand G, et al. Immunsuppressive Basistherapie nach Nierentransplantation: Cyclosporin-A in Kombination mit kleinen Dosen von Methylprednisolon, ohne Berücksichtigung von Ausschlusskriterien Vorläufige Mitteilung. Fortschr Med 1982; 100: 1912–6.
13. Canafax DM, Martel EJ, Ascher NL, et al. Two methods of managing cyclosporine nephrotoxicity: conversion to azathioprine, prednisone, or cyclosporine, azathioprine, and prednisone. Transplant Proc 1985; 17: 1176–7.
14. Rechner SM, Lorber M, Van Buren C, Kerman R, Kahan BD. The case against conversion to azathioprine cyclosporine-treated renal recipients. Transplant Proc 1985; 17: Suppl 1: 276–81.
15. Disney ASP. Adverse effects of low-dose azathioprine on Australian primary graft survival (1978–1984). Transplant Proc 1987; 19: 1981–4.
16. Ray JG. Hare DB, Pederson PD, et al. Manual of tissue typing. Washington, D.C.: Government Printing Office, 1975:20. (DHEW publication no. (NIH) 74–545.)
17. Wood AJ, Lemaire M. Pharmacologic aspects of cyclosporine therapy: pharmacokinetics. Transplant Proc 1985; 17: Suppl 1: 27–32.
18. d'Apice AJF, Becker GJ, Kincaid-Smith P, et al. A prospective randomized trial of low-dose versus high-dose steroids in cadaveric renal transplantation. Transplantation 1984; 37: 373–7.
19. Sheil AG, Kelly GE, Mears D, et al. Antilymphocyte globulin in patients with renal allografts from cadaveric donors: late results of a controlled trial. Lancet 1973; 1: 227–31.
20. Farnsworth A, Hall BM, Ng ABP, et al. Renal biopsy morphology in renal transplantation: a comparative study of the light-microscopic appearances of biopsies from patients treated with cyclosporin A or azathioprine prednisone and antilymphocyte globulin. Am J Surg Pathol 1984; 8: 243–52.
21. Mihatsh MJ, Theil G, Spicktin WP, et al. Findings in kidney transplants after treatment with cyclosporine. Transplant Proc 1983; 15: Suppl 1: 2821–35.
22. Whitehurst RM, Innes JT, Sommers BG, Ferguson RM, Sharma HM. Vascular toxicity associated with cyclosporin (CYA) treatment of renal transplants. Am J Clin Pathol 1985; 83: 270–1.
23. Morris PJ, Chapman JR, Allen RD, et al. Cyclosporine conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987; 1: 586–90.
24. Hoitsma AJ, Wetzels JFM, Van Lier HJJ, Berden JHM, Koene RAP. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1987; 1: 584–6.
25. Curtis JJ, Luke RG, Dubovsky E, Diethelm AG, Whelchel JD, Jones P. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; 2: 477–9.
26. Rocher LL, Milford EL, Kirkman RL, Carpenter CB, Strom TB, Tilney NL. Conversion from cyclosporine to azathioprine in renal allograft recipients. Transplantation 1984; 38: 669–74.
27. Macdonald AS, Belitsky P, Gupta R, et al. Conversion from cyclosporine to azathioprine in renal graft recipients. Transplant Proc 1985; 17: 1940–2.
28. Thistlethwaite JR Jr, Haag BW, Jones KW, Stuart JK, Stuart FP. Elective conversion from cyclosporine to azathioprine in recipients with stable renal function 6 months after kidney transplantation. Hum Immunol 1985; 14: 314–23.
29. Opelz G, for the Collaborative Transplant Study. Effect of HLA matching, blood transfusions, and presensitization in cyclosporine-treated kidney transplant recipients. Transplant Proc 1985; 17: 2179–83.
30. d'Apice AJF, Sheil AGR, Tait BD, Bashir HV. A prospective randomized trial of matching for HLA-A and B versus HLA-DR in renal transplantation. Transplantation 1984; 38: 37–41.
31. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590–600.
32. Vanrenterghem Y, Roels L, Lernt T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985; 1: 999–1002.
33. Chapman JR, Griffiths D, Harding NGL, Morris PJ. Reversibility of cyclosporin nephrotoxicity after three months' treatment. Lancet 1985; 1: 128–30.
34. Hall BM, Tiller DJ, Duggin GG, et al. Post-transplant acute renal failure in cadaver renal recipients treated with cyclosporine. Kidney Int 1985; 28: 178–86.
35. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219–25.
36. Merion RM, White DJG, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148–54.
37. Lorber MI, Flechner SM, Van Buren CT, Sorensen K, Kerman RH, Kahan BD. Management of immunosuppressive problems in renal allograft recipients. Transplant Proc 1987; 19: 1951–4.
38. Mahony JF, Sheil AG, Etheredge SB, Storey BG, Stewart JH. Delayed complications of renal transplantation and their prevention. Med J Aust 1982; 2: 426–9.
39. Sheil AGR, Flavel S, Disney APS, Mathew TH, Hall BM. Cancer incidence in renal transplant patients treated with azathioprine or cyclosporine. Transplant Proc 1987; 19: 2214–6.